Dr. Angelos Stergiou’s SELLAS Life Sciences Group licensed from Memorial Sloan Kettering Cancer Center the immunotherapeutic Galinpepimut-S, which is about to begin Phase III clinical trials in AML and Mesothelioma patients in 2017. Galinpepimut-S is also being developed for multiple myeloma, ovarian cancer and uses alone and in combination with various immune-oncology agents.
Future trials are planned for therapies for chronic Myelogenous Leukemia and Glioblastoma Multiforme. Dr. Angelos Stergiou, the founder and Chief Executive Officer, recently announced that SELLAS Life Sciences Group has a Cooperative Research and Development Agreement with the US National Heart, Lung and Blood Institute of the National Institutes of Health. SELLAS and its management team can provide proof of successful development and commercialization of drugs and cancer therapeutics and its management also has taken companies public, provided out-licensing of drug candidates, has formed research and development partnerships and is proud of its multiple alliances with other top ranking research and medical centers in the past.
Chief Executive Officer and Vice Chairman of SELLAS, Dr. Angelos Stergiou has been a professional in a variety of roles, including Medical Director, Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Officer. With responsibilities from medical affairs to clinical research and development to pharma covigilance, Stergiou has also overseen clinical operations, project management, regulatory affairs, biostatistics and chemistry and manufacturing and controls. Dr. Stergiou’s fluence in German, Greek and English has made his management and operations expertise even more effective. In the process, Dr. Stergiou had co-founded Genesis Life Sciences, a New York based health, economics and pricing reimbursement and health access company.
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly